BioCentury
ARTICLE | Clinical News

Eflornithine/sulindac: Completed Phase III enrollment

April 11, 2016 7:00 AM UTC

Cancer Prevention completed enrollment of 166 FAP patients in a double-blind, placebo-controlled, international Phase III trial comparing 750 mg oral eflornithine once daily plus 150 mg oral sulindac ...